Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset
Mereo BioPharma’s asset, dubbed alvelestat, is set to enter Phase 3 development for AATD-LD in 2027.
Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset Read More »
